SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Jenkins John Kenneth					2. Issuer Name and Ticker or Trading Symbol <u>Corbus Pharmaceuticals Holdings, Inc.</u> [CRBP]										tionship of R all applicab Director		Person	(s) to Issuer 10% Ov	vner
(Last)	(First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 05/18/2023										Officer (g below)	ive title		Other (s below)	specify
C/O CORBUS PHARMACEUTICALS HOLDINGS,INC. 500 RIVER RIDGE DRIVE					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Indiv X	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Street) NORWOOD (City)	MA (State)		2062 (ip)												Form file	d by More	than C	one Reportin	g Person
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				th/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr.			ities Acqu d Of (D) (I			5. Amount Securities Beneficially Following	y Owned or Reported (Ins		/nership : Direct (D) lirect (I) . 4)	7. Nature of Indirect Beneficial Ownership	
			Code					v	Amount		A) or D)	Price	Transactio (Instr. 3 and				(Instr. 4)		
			Table II -								sed of, o onvertib				ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	nte, Ti	4. Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	ode	v	(A)	(D)	Date Exercisal		Expiration Date	Title		Amount or Number of Shares		(Instr. 4)	ion(s)		
Stock Option (right to buy)	\$9.96	05/18/2023			Α		5,300		(1)	-	05/18/2033	Comr		5,300	\$0.00	5,300	0	D	

Explanation of Responses:

1. The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest 100% on the one year anniversay from the date of grant.

Remarks:

/s/ Sean Moran, attorney-in-fact	05/22/2023
for John Jenkins	05/22/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.